Showing results (521-530 of 632) with videos related to

Sort By:
Pageof 64
AIDS (London, England)|August 7, 2019
Serious clinical events in HIV-positive persons with chronic kidney diseaseLene Ryom, Jens D Lundgren, Matthew Law, et al.
Antiviral Therapy|May 29, 2008
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trialAndrew N Phillips, Andrew Carr, Jacquie Neuhaus, et al.
HIV Medicine|May 21, 2014
Increased risk of cardiovascular disease (CVD) with age in HIV-positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equationsK Petoumenos, P Reiss, L Ryom, et al.
The Lancet. Global Health|September 21, 2023
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysisAndrew N Phillips, Loveleen Bansi-Matharu, Maryam Shahmanesh, et al.
AIDS (London, England)|March 8, 2016
Improvements over time in short-term mortality following myocardial infarction in HIV-positive individualsCamilla Ingrid Hatleberg, Lene Ryom, Wafaa El-Sadr, et al.
AIDS (London, England)|August 19, 2004
Cardio- and cerebrovascular events in HIV-infected personsA d'Arminio, C A Sabin, A N Phillips, et al.
The Lancet. HIV|January 21, 2018
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trialJean-Michel Molina, Birgit Grund, Fred Gordin, et al.
AIDS (London, England)|September 16, 2015
Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSMAndrew N Phillips, Valentina Cambiano, Alec Miners, et al.
The Journal of Infectious Diseases|April 2, 2016
Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan AfricaAndrew N Phillips, Valentina Cambiano, Paul Revill, et al.
AIDS (London, England)|January 8, 2013
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease eventsAntonella d'Arminio Monforte, Peter Reiss, Lene Ryom, et al.
Pageof 64